Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). 47th Annual Meeting of the American-Society-of-Hematology Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., MILLER, R. A., Phan, S. C. AMER SOC HEMATOLOGY. 2005: 269B–270B

View details for Web of Science ID 000233426101460